Study Name:
Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant with Pembrolizumab and Platinum Based Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer
Targeted Disease(s):
Lung Cancer
Purpose of Study:
The purpose of the study is to test the effectiveness and safety of TTFields, delivered using the NovoTTF-200T device, concomitant with pembrolizumab and platinum-based chemotherapy in subjects with metastatic non-small cell lung cancer (NSCLC). The NovoTTF-200T is intended to extend the overall survival and/or the progression free survival in the study population of subjects with metastatic NSCLC who have not received prior systemic treatment for metastatic disease.
Study Dates:
July 31, 2024 - October 31, 2028
Type of Study:
Pre-Market
Study Design:
Controlled Design
Study Location:
Nationwide
Sponsors:
Novocure Gmbh
Contact:
Donald Carlino
610-505-4492
[email protected]
ClinicalTrails.gov Identifier:
NCT06216301
